Novartis leverages digital transformation to address most pressing health challenges in Asia

PR77411

SINGAPORE, Feb. 13, 2019 /PRNewswire=KYODO JBN/ --

Novartis is on a mission to transform healthcare in Asia by partnering with the

health tech ecosystem.

Photo - https://photos.prnasia.com/prnh/20181218/2330634-1

"Novartis in Asia seeks to leverage data, digital and exponential technologies

to address the most pressing health challenges in the region. From Big Data,

Machine Learning, Telemedicine, the use of sensors to Virtual Reality -- we aim

to harness all these technologies to create disruptive opportunities, transform

the healthcare landscape and save lives. This is why we are partnering with key

heath-tech startups in Asia to equip our company in bringing transformative

healthcare solutions to patients," said Alexis Serlin, Head of Asia Cluster,

Novartis AG.

With an industry-leading development pipeline, Novartis is well positioned to

spearhead a transformative revolution in healthcare. The Novartis pipeline has

26 potential blockbusters in confirmatory development and 13 projects in

clinical development across Cell, Gene & Radioligand therapies, with 60 major

submissions planned from 2019 to 2021. Novartis is advancing a pipeline of

medicines with the potential to change the standard of care in high-burden

disease areas, such as multiple sclerosis, asthma, age-related macular

degeneration, sickle cell disease, and lung cancer.[1] The quality and

consistency of Novartis' R&D is reflected in its #1 position as the company

with the highest number of Breakthrough Therapy Designations (BTDs), a key

measure of innovation. Between 2005 and 2018, Novartis secured regulatory

approval for more new drugs than any other pharmaceutical company.[2]

According to Mr. Serlin, Novartis intends to map the health-tech space in Asia,

particularly start-ups focused on enhancing healthcare delivery avenues, such

as improving patient outcomes, transforming patient journeys, and creating

differentiated and transformational customer engagement models, among others.

"There are a lot of health-tech start-ups in Asia brimming with

transformational business ideas, and we intend to incubate them," said Serlin.

To this end, Novartis Asia in partnership with Galen Growth Asia held its first

Asia Business Model Transformation Workshop last November in Singapore. The

workshop aimed to connect senior Novartis leaders in Asia with health-tech

startups in the region to co-create solutions to keep people well and keep them well.

"We are delighted to partner with Novartis on its digital business

transformation journey, leveraging our unique and extensive data analytics,

insights and network drawn from the $75B Asia Pacific HealthTech ecosystem, the

second largest in the world," said Julien de Salaberry, CEO & Founder of Galen

Growth Asia.

References:

[1]

https://www.novartis.com/news/media-releases/novartis-rd-update-highlights-industry-leading-development-pipeline-including-potential-blockbusters-and-advanced-therapy-platforms

[2] Intrinsic Health/New Street Research. Novartis: Time for a Premium

Multiple.

SOURCE Novartis